Antimetastatic, antineoplastic, and toxic effects of 4-hydroxycoumarin in a preclinical mouse melanoma model

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 5, 2010, Pages 931-940

  Salinas Jazmín, Nohemí ^a   De La Fuente, Marisol ^b   Jaimez, Ruth ^a   Pérez Tapia, Mayra ^b   Pérez Torres, Armando ^c   Velasco Velázquez, Marco A ^a  

^a Ciudad Universitaria ^*  (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

4 Hydroxycoumarin; Coumarin; Melanoma; Metastasis

Indexed keywords

4 HYDROXYCOUMARIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRONCHUS MUCOSA; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; HISTOLOGY; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VIVO STUDY; LUNG METASTASIS; MALE; MELANOMA; METASTASIS INHIBITION; MOUSE; NEPHRON; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL TIME;

4-HYDROXYCOUMARINS; ANIMALS; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; KIDNEY; LIVER; LUNG; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS;

EID: 77649180895     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1100-z     Document Type: Article

References (54)

1. C Garbe U Leiter 2009 Melanoma epidemiology and trends Clin Dermatol 27 3 9 10.1016/j.clindermatol.2008.09.001 19095149
2. Ries LAG, Melbert D, Krapcho M et al (2008) SEER cancer statistics review, 1975-2005. National Cancer Institute, Bethesda, MD
3. CM Balch SJ Soong MB Atkins, et al. 2004 An evidence-based staging system for cutaneous melanoma CA Cancer J Clin 54 131 149 10.3322/canjclin.54.3.131 15195788 quiz 182-134
4. T Bogenrieder M Herlyn 2003 Axis of evil: molecular mechanisms of cancer metastasis Oncogene 22 6524 6536 10.1038/sj.onc.1206757 14528277
5. JD Hood DA Cheresh 2002 Role of integrins in cell invasion and migration Nat Rev Cancer 2 91 100 10.1038/nrc727 12635172
6. S Hehlgans M Haase N Cordes 2007 Signalling via integrins: implications for cell survival and anticancer strategies Biochim Biophys Acta 1775 163 180 17084981
7. MA Velasco-Velazquez JA Molina-Guarneros N Mendoza-Patino, et al. 1999 Integrins and integrin-associated molecules: targets for the development of antimetastatic therapies Rev Invest Clin 51 183 193 10466009
8. MA Velasco-Velazquez N Salinas-Jazmin N Mendoza-Patino JJ Mandoki 2008 Reduced paxillin expression contributes to the antimetastatic effect of 4-hydroxycoumarin on B16-F10 melanoma cells Cancer Cell Int 8 8 10.1186/1475-2867-8-8 18492274
9. MA Velasco-Velazquez J Agramonte-Hevia D Barrera, et al. 2003 4-Hydroxycoumarin disorganizes the actin cytoskeleton in B16-F10 melanoma cells but not in B82 fibroblasts, decreasing their adhesion to extracellular matrix proteins and motility Cancer Lett 198 179 186 10.1016/S0304-3835(03)00333-1 12957356 (Pubitemid 37297791)
10. (1988) UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 58:109-113
11. AJ Quick 1974 Letter: normal values for coagulation tests N Engl J Med 290 751 4813756
12. RR Proctor SI Rapaport 1961 The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies Am J Clin Pathol 36 212 219 13738153
13. Z Qi I Whitt A Mehta, et al. 2004 Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance Am J Physiol Renal Physiol 286 F590 F596 10.1152/ajprenal.00324.2003 14600035
14. Mohr U, Dungworth DL, Capen CC et al (1996) Pathobiology of the aging mouse. ILSI Press, Washington, DC
15. AC Luchini P Rodrigues-Orsi SH Cestari, et al. 2008 Intestinal anti-inflammatory activity of coumarin and 4-hydroxycoumarin in the trinitrobenzenesulphonic acid model of rat colitis Biol Pharm Bull 31 1343 1350 10.1248/bpb.31.1343 18591772 (Pubitemid 351930644)
16. T Stefanova N Nikolova A Michailova, et al. 2007 Enhanced resistance to Salmonella enterica serovar Typhimurium infection in mice after coumarin treatment Microbes Infect 9 7 14 10.1016/j.micinf.2006.10.001 17196418 (Pubitemid 46149413)
17. TH Stefanova NJ Nikolova RA Toshkova HO Neychev 2007 Antitumor and immunomodulatory effect of coumarin and 7-hydroxycoumarin against Sarcoma 180 in mice J Exp Ther Oncol 6 107 115 17407969
18. Orozco Arreaga A (2000) Estudio in vivo del efecto antineoplasico de la cumarina en un modelo de melanoma murino. Dissertation, Universidad Nacional Autónoma de México
19. Cruzan G, Bus J, Banton M et al (2009) Mouse specific lung tumors from CYP2F2-mediated cytotoxic metabolism: an endpoint/toxic response where data from multiple chemicals converge to support a mode of action. Regul Toxicol Pharmacol. doi: 10.1016/j.yrtph.2009.07.002
20. SL Born AM Api RA Ford, et al. 2003 Comparative metabolism and kinetics of coumarin in mice and rats Food Chem Toxicol 41 247 258 10.1016/S0278-6915(02) 00227-2 12480300 (Pubitemid 35447874)
21. S Kawaii Y Tomono K Ogawa, et al. 2001 The antiproliferative effect of coumarins on several cancer cell lines Anticancer Res 21 917 923 11396185
22. D Barkan H Kleinman JL Simmons, et al. 2008 Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton Cancer Res 68 6241 6250 10.1158/0008-5472.CAN-07-6849 18676848
23. FH Dexeus CJ Logothetis A Sella, et al. 1990 Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma J Clin Oncol 8 325 329 2137163
24. JL Mohler BT Williams IM Thompson ME Marshall 1994 Coumarin (1, 2-benzopyrone) for the treatment of prostatic carcinoma J Cancer Res Clin Oncol 120 Suppl S35 S38 10.1007/BF01377123 8132702
25. ME Marshall K Kervin C Benefield, et al. 1994 Growth-inhibitory effects of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin on human malignant cell lines in vitro J Cancer Res Clin Oncol 120 Suppl S3 S10 10.1007/BF01377114 7510710
26. FA Jimenez-Orozco JA Molina-Guarneros N Mendoza-Patino, et al. 1999 Cytostatic activity of coumarin metabolites and derivatives in the B16-F10 murine melanoma cell line Melanoma Res 9 243 247 10465579
27. JS Lopez-Gonzalez H Prado-Garcia D Aguilar-Cazares, et al. 2004 Apoptosis and cell cycle disturbances induced by coumarin and 7-hydroxycoumarin on human lung carcinoma cell lines Lung Cancer 43 275 283 10.1016/j.lungcan.2003.09.005 15165085 (Pubitemid 38224147)
28. FA Jimenez-Orozco JS Lopez-Gonzalez A Nieto-Rodriguez, et al. 2001 Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin Lung Cancer 34 185 194 10.1016/S0169-5002(01)00263-X 11679177
29. NB Piller 1978 A morphological assessment of the stimulatory effect of coumarin on macrophages Br J Exp Pathol 59 93 96 638035
30. TJ Hardt WA Ritschel 1983 The effect of coumarin and 7-hydroxycoumarin on in vitro macrophage phagocytosis of latex particles Methods Find Exp Clin Pharmacol 5 39 43 6855342
31. J Villanueva M Herlyn 2008 Melanoma and the tumor microenvironment Curr Oncol Rep 10 439 446 10.1007/s11912-008-0067-y 18706274
32. D Ratanasavanh D Lamiable M Biour, et al. 1996 Metabolism and toxicity of coumarin on cultured human, rat, mouse and rabbit hepatocytes Fundam Clin Pharmacol 10 504 510 10.1111/j.1472-8206.1996.tb00607.x 8985719
33. NTP (National Toxicology Program) 1993 NTP toxicology and carcinogenesis studies of coumarin (CAS No. 91-64-5) in F344/N rats and B6C3F1 mice (gavage studies) Natl Toxicol Program Tech Rep Ser 422 1 340
34. AJ Cohen 1979 Critical review of the toxicology of coumarin with special reference to interspecies differences in metabolism and hepatotoxic response and their significance to man Food Cosmet Toxicol 17 277 289 10.1016/0015-6264(79) 90289-X 387555 (Pubitemid 10224817)
35. BG Lake 1984 Investigations into the mechanism of coumarin-induced hepatotoxicity in the rat Arch Toxicol Suppl 7 16 29 6595978
36. JD Vassallo SM Hicks GP Daston LD Lehman-McKeeman 2004 Metabolic detoxification determines species differences in coumarin-induced hepatotoxicity Toxicol Sci 80 249 257 10.1093/toxsci/kfh162 15141102 (Pubitemid 39136379)
37. BG Lake JG Evans DF Lewis RJ Price 1994 Comparison of the hepatic effects of coumarin, 3,4-dimethylcoumarin, dihydrocoumarin and 6-methylcoumarin in the rat Food Chem Toxicol 32 743 751 10.1016/S0278-6915(09)80007-0 8070739
38. BG Lake TJ Gray JG Evans, et al. 1989 Studies on the mechanism of coumarin-induced toxicity in rat hepatocytes: comparison with dihydrocoumarin and other coumarin metabolites Toxicol Appl Pharmacol 97 311 323 10.1016/0041-008X(89)90336-0 2922762 (Pubitemid 19079059)
39. JD Vassallo SM Hicks SL Born GP Daston 2004 Roles for epoxidation and detoxification of coumarin in determining species differences in clara cell toxicity Toxicol Sci 82 26 33 10.1093/toxsci/kfh237 15282406 (Pubitemid 39485317)
40. D Cox R O'Kennedy RD Thornes 1989 The rarity of liver toxicity in patients treated with coumarin (1,2-benzopyrone) Hum Toxicol 8 501 506 10.1177/096032718900800612 2591993
41. JR Casley-Smith 1995 Frequency of coumarin hepatotoxicity Med J Aust 162 391 7715532
42. Pelkonen O, Raunio H, Rautio A, Pasanen M (1997) The metabolism of coumarin. In: O'Kennedy R, Thornes RD (eds) Coumarins biology, applications and mode of action. Wiley, New York
43. SL Born AS Fix D Caudill LD Lehman-McKeeman 1999 Development of tolerance to Clara cell necrosis with repeat administration of coumarin Toxicol Sci 51 300 309 10.1093/toxsci/51.2.300 10543032 (Pubitemid 29496237)
44. SL Born AS Fix D Caudill LD Lehman-McKeeman 1998 Selective Clara cell injury in mouse lung following acute administration of coumarin Toxicol Appl Pharmacol 151 45 56 10.1006/taap.1998.8442 9705886 (Pubitemid 28406650)
45. X Zhuo J Gu QY Zhang, et al. 1999 Biotransformation of coumarin by rodent and human cytochromes P-450: metabolic basis of tissue-selective toxicity in olfactory mucosa of rats and mice J Pharmacol Exp Ther 288 463 471 9918546
46. SL Born D Caudill KL Fliter MP Purdon 2002 Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation Drug Metab Dispos 30 483 487 10.1124/dmd.30.5.483 11950775 (Pubitemid 34456966)
47. PT Nhamburo S Kimura OW McBride, et al. 1990 The human CYP2F gene subfamily: identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression, and chromosome mapping Biochemistry 29 5491 5499 10.1021/bi00475a012 1974816 (Pubitemid 20202273)
48. RM Baldwin WT Jewell MV Fanucchi, et al. 2004 Comparison of pulmonary/nasal CYP2F expression levels in rodents and rhesus macaque J Pharmacol Exp Ther 309 127 136 10.1124/jpet.103.062901 14724224 (Pubitemid 38393123)
49. X Ye L Lu SS Gill 1997 Suppression of cytochrome P450 Cyp2f2 mRNA levels in mice by the peroxisome proliferator diethylhexylphthalate Biochem Biophys Res Commun 239 660 665 10.1006/bbrc.1997.7529 9367824 (Pubitemid 27504157)
50. T Su W He J Gu, et al. 1998 Differential xenobiotic induction of CYP2A5 in mouse liver, kidney, lung, and olfactory mucosa Drug Metab Dispos 26 822 824 9698299
51. K Dahri P Loewen 2007 The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules Thromb Haemost 98 980 987 18000602
52. RL Mueller S Scheidt 1994 History of drugs for thrombotic disease. Discovery, development, and directions for the future Circulation 89 432 449 8281678
53. LB von Weymarn SE Murphy 2003 CYP2A13-catalysed coumarin metabolism: comparison with CYP2A5 and CYP2A6 Xenobiotica 33 73 81 10.1080/ 0049825021000022302 (Pubitemid 36071764)
54. D Egan R O'Kennedy E Moran, et al. 1990 The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds Drug Metab Rev 22 503 529 10.3109/03602539008991449 2078993